Consensus Champions Oncology, Inc.

Equities

CSBR

US15870P3073

Delayed Nasdaq Other stock markets 11:09:55 2024-04-19 am EDT			5-day change	1st Jan Change
5.1 ^USD	+0.69%		+2.00%	-9.25%

Mar. 15	Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023.	CI
Mar. 13	Craig-Hallum Downgrades Champions Oncology to Hold From Buy	MT

Evolution of the average Target Price on Champions Oncology, Inc.

Price target over the last 5 years

History of analyst recommendation changes

f75c129d35d60837760d2.FMluKegNbOUGxS_AnAtejZ3Tx7jj9tZLV-zS8y-dA2g.Tr8iW709Fshup2X3qm0NyKqbj46PopV4Ot-5tmjrNRFTkFp7nmYHgTbyag~ca491da6423cc7e6dabba920679e601c

Analyst Recommendations on Champions Oncology, Inc.

Craig-Hallum Downgrades Champions Oncology to Hold From Buy	Mar. 13	MT
Craig Hallum Trims Champions Oncology Price target to $9 From $10, Maintains Buy Rating	Dec. 13	MT
Roth MKM Adjusts Price Target on Champions Oncology to $7.50 From $9, Maintains Buy Rating	23-09-22	MT
Benchmark Company Downgrades Champions Oncology to Hold From Speculative Buy	23-03-16	MT
Craig Hallum Adjusts Champions Oncology Price Target to $10 From $12, Maintains Buy Rating	23-03-16	MT
CHAMPIONS ONCOLOGY : Roth Capital Adjusts Price Target on Champions Oncology to $16 From $13.50, Maintains Buy Rating	21-03-15	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

5.065 USD

Average target price

6 USD

Spread / Average Target

+18.46%

High Price Target

6 USD

Spread / Highest target

+18.46%

Low Price Target

6 USD

Spread / Lowest Target

+18.46%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Champions Oncology, Inc.

Craig-Hallum
Roth MKM
Benchmark Company
Roth Capital Partners

Quarterly earnings - Rate of surprise

Company calendar